COMPARE · Data as of August 24, 2026

ISRG vs RDNT

Verdict: Side-by-side breakdown using the Bull Rankings model. ISRG scored 74.2, RDNT scored 56.1 — ISRG leads.
Compare another set
ISRG
Intuitive Surgical, Inc.
Medical Instruments & Supplies · Quality-Growth
74.2
$373.57 · $133.8B
fundamentals as of
Score gap
18.1
ISRG leads
RDNT
RadNet, Inc.
Diagnostics & Research · Quality-Growth
56.1
$74.69 · $5.9B
fundamentals as of
  • Fastest growthISRG+20.7%
  • Highest qualityISRG84 / 100
THE BULL RANKINGS SCORECARD74.2/ 100 · BULL SCOREPEER MEDIANQUALITY83.7GROWTH93.2VALUE52.3
THE BULL RANKINGS SCORECARD56.1/ 100 · BULL SCOREPEER MEDIANQUALITY35.2GROWTH86.5VALUE58.1
ISRGRDNTQuality83.735.2Growth93.286.5Value52.358.1
FCFISRG$3.2bRDNT$236m
RevISRG+20.7%RDNT+18.9%
PEGISRG1.86RDNT0.96
ISRG
stronger →← stronger
RDNT
84
Qualityreturns · margins · balance sheet
35
93
Growthrevenue & earnings expansion
86
52
Valuevaluation vs sector peers
58
ISRG is stronger on 2 of 3 pillars.
ISRG
RDNT
$3.2bB
FCF
$236mC
+20.7%A-
Rev
+18.9%B+
D/E
1.57C
43.5xC
P/E
1.86C+
PEG
0.96B+
P/S
2.6xB+
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
ISRG
RDNT
217% above
Price vs fair valuelower is cheaper
39% above
~40%/yr
Growth the price implies10-yr FCF · lower = less priced in
~24%/yr
-72%
1-yr DCF upside
-45%
-68%
5-yr DCF upside
-28%
-63%
10-yr DCF upside
+5%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
ISRG
No notable signals flagged.
RDNT
Why this score
  • Diluting shareholders
ISRGIntuitive Surgical, Inc.
Medical Instruments & Supplies · $373.57 · beta 1.46
Why now
Medical Instruments & Supplies · market cap $133.8b. Down 38% from 52-week high of $603.88 — deep drawdown territory. Revenue growing +21%, comfortably above the S&P median. 30 sell-side analysts rate this a Buy with a mean 1-yr target of $478.01 (implying +28% upside).
Moat
Net margin 28% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 17% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 103% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Down 38% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 1.46 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 43x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
RDNTRadNet, Inc.
Diagnostics & Research · $74.69 · beta 1.38
Why now
Diagnostics & Research · market cap $5.9b. 13% off the 52-week high of $85.84. Revenue growing +19%, comfortably above the S&P median. PEG 0.96 — paying under fair value for the growth rate. 8 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $92.88 (implying +24% upside).
Moat
Turnaround / out-of-favor name — GAAP-unprofitable for now, so the durability case is forward-looking: it rests on a recovery (margin normalization, a cyclical upturn or restructuring) or an un-monetized asset (IP / network effects / first-mover position) rather than on current reported results.
Risk
Currently unprofitable (margin -0.9%) — path to GAAP profitability is the core thesis risk. ROE -2% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.

Where ISRG and RDNT diverge

On the headline score the gap is 18.1 points in favor of ISRG. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.

Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.